Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on March 11. The event will focus on discovering and developing medicines for serious and rare diseases.
03/05/2024 - 08:00 AM
WALTHAM, Mass. --(BUSINESS WIRE)--
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.
A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com . A replay of the webcast will be available following the completion of the event.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in Waltham, Massachusetts . For more information, please visit www.viridiantherapeutics.com . Follow Viridian on LinkedIn and X .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305448281/en/
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
When is Viridian Therapeutics participating in the Leerink Partners Global Biopharma Conference?
Viridian Therapeutics will participate in the Leerink Partners Global Biopharma Conference on Monday, March 11 at 2:00 p.m. ET.
What is the focus of Viridian Therapeutics as a biopharmaceutical company?
Viridian Therapeutics focuses on discovering and developing potential best-in-class medicines for serious and rare diseases.
Where can the live webcast of the fireside chat be accessed?
The live webcast of the fireside chat can be accessed under 'Events and Presentations' on the Investors section of the Viridian website at viridiantherapeutics.com.
Will there be a replay of the webcast available?
Yes, a replay of the webcast will be available following the completion of the event.
Viridian Therapeutics Inc
VRDN Rankings
#4219 Ranked by Stock Gains
VRDN Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Country
US
City
Boulder
About VRDN
miragen therapeutics, inc., (nasdaq: mgen), is a biopharmaceutical company discovering and developing innovative microrna (mirna)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. the company leverages in-house expertise in mirna biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. at miragen, we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. this collaborative approach is making important contributions in our efforts to create mirna-targeting therapies. miragen’s areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. in 2011, the company formed a strategic partnership with servier, a privately-run, french research